These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1815 related items for PubMed ID: 28993143
1. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [Abstract] [Full Text] [Related]
2. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M. J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046 [Abstract] [Full Text] [Related]
3. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). Pfaller MA, Bassetti M, Duncan LR, Castanheira M. J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526 [Abstract] [Full Text] [Related]
6. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK. Braz J Infect Dis; 2017 May 01; 21(6):627-637. PubMed ID: 28941394 [Abstract] [Full Text] [Related]
7. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Seifert H, Körber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study Group. Int J Antimicrob Agents; 2018 Feb 01; 51(2):227-234. PubMed ID: 28705666 [Abstract] [Full Text] [Related]
8. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group. Int J Antimicrob Agents; 2015 Nov 01; 46(5):502-10. PubMed ID: 26315199 [Abstract] [Full Text] [Related]
13. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group. Antimicrob Agents Chemother; 2019 Apr 01; 63(4):. PubMed ID: 30617091 [Abstract] [Full Text] [Related]
14. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Grupper M, Sutherland C, Nicolau DP. Antimicrob Agents Chemother; 2017 Oct 01; 61(10):. PubMed ID: 28739780 [Abstract] [Full Text] [Related]
15. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS, Farrell DJ, Flamm RK, Jones RN. J Infect; 2014 Sep 01; 69(3):266-77. PubMed ID: 24780763 [Abstract] [Full Text] [Related]
16. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Henderson A, Tan E, McCarthy KL, Paterson DL. Pathology; 2018 Dec 01; 50(7):748-752. PubMed ID: 30392710 [Abstract] [Full Text] [Related]
17. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study. García-Fernández S, García-Castillo M, Bou G, Calvo J, Cercenado E, Delgado M, Pitart C, Mulet X, Tormo N, Mendoza DL, Díaz-Regañón J, Cantón R, SUPERIOR Study Group. Int J Antimicrob Agents; 2019 May 01; 53(5):682-688. PubMed ID: 30769199 [Abstract] [Full Text] [Related]
18. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrob Agents Chemother; 2013 Dec 01; 57(12):6305-10. PubMed ID: 24100499 [Abstract] [Full Text] [Related]
19. In silico and In vitro activity of ceftolozane/tazobactam against pseudomonas aeruginosa collected across Indian hospitals. Pragsam AK, Kumar DT, Doss CGP, Iyadurai R, Satyendra S, Rodrigues C, Joshi S, Roy I, Chaudhuri BN, Chitnis DS, Tapan D, Veeraraghavan B. Indian J Med Microbiol; 2018 Dec 01; 36(1):127-130. PubMed ID: 29735843 [Abstract] [Full Text] [Related]
20. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018. Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M. J Glob Antimicrob Resist; 2022 Dec 01; 31():98-103. PubMed ID: 35988706 [Abstract] [Full Text] [Related] Page: [Next] [New Search]